Pay in 4 interest-free payments of $6.87 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
In clinical trials, the results were impressive: a median survival rate of 177.1 months for the early treatment Zycubo cohort compared with only 17.6 months for the untreated external cohort
Consistency within a protocol cycle is important
180 In preclinical models of breast cancer, some novel nanomedicines that target cuproptosis have demonstrated efficacy in inhibiting tumor growth and may hold potential for future clinical applications
doi: 10.1097/DCR.0000000000001127 9RakinicJ, PoolaVP
US$ 23.80
US$ 29.14
US$ 26.92
US$ 22.47
US$ 20.60
US$ 26.13
